BMS, Pfizer and Portola team up to bring andexanet alfa to Japan
1 February 2016 | By Victoria White
Andexanet alfa is designed to reverse the anticoagulant activity of Factor Xa inhibitors, including Eliquis (apixaban)...
List view / Grid view
1 February 2016 | By Victoria White
Andexanet alfa is designed to reverse the anticoagulant activity of Factor Xa inhibitors, including Eliquis (apixaban)...
22 June 2015 | By Victoria White
Full results from the second part of a Phase 3 trial evaluating the safety and efficacy of andexanet alfa as a reversal agent of Eliquis have been announced...
18 November 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and Pfizer Inc. announced results from the first part of the Phase 3 ANNEXA™-A (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of fXA Inhibitors – Apixaban) studies...